In Q1 FY2026 (ending March 31, 2026), Prelude Therapeutics reported revenue of $4.58 million, a net loss of $10.39 million (improved 67.6% year-over-year), and an operating loss of $14.18 million (improved 59.0% year-over-year). Diluted EPS was -$0.13, also improving 69.0% from the prior year. The company held $21.76 million in cash and $60.18 million in equity, with no long-term debt.
•Revenue of $4.58 million in Q1 FY2026.
•Net loss narrowed to $10.39 million, a 67.6% improvement year-over-year.
•Operating loss improved 59.0% to $14.18 million.
•Cash and equivalents of $21.76 million; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company focuses on the discovery and development of novel precision cancer medicines to underserved patients.
It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET). Its portfolio also includes KAT6A for the treatment of advanced breast cancer and solid tumors, and mutated calreticulin degrader antibody conjugates to treat MF and ET.
The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
What does Prelude Therapeutics Incorporated (PRLD) do?
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel precision cancer medicines for underserved patients. Its lead program targets the JAK2V617F driver mutation, which is being developed for myeloproliferative neoplasms, including myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET). The company also has a KAT6A program for advanced breast cancer and solid tumors, as well as mutated calreticulin degrader antibody conjugates for MF and ET. Additionally, Prelude has a collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates.
Where is Prelude Therapeutics Incorporated (PRLD) listed and what currency is used?
Prelude Therapeutics Incorporated is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PRLD. The company's stock is traded in US Dollars (USD), as it is headquartered in the United States. Being listed on NasdaqGS provides the company with access to a broad base of institutional and retail investors, and it must meet stringent listing requirements regarding market capitalization, financial standards, and corporate governance.
What sector and industry does Prelude Therapeutics (PRLD) operate in?
Prelude Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on using biological processes and molecular biology to develop therapies. More precisely, it is a clinical-stage precision oncology company, meaning it targets specific genetic mutations or molecular pathways in cancer cells to create more effective and less toxic treatments. The company's pipeline includes small molecule inhibitors and antibody conjugates designed to address unmet medical needs in hematologic cancers and solid tumors.
Where is Prelude Therapeutics (PRLD) headquartered and what is its history?
Prelude Therapeutics is headquartered in Wilmington, Delaware, United States. The company was incorporated in 2016, making it a relatively young biotechnology firm. Its focus on precision oncology reflects a modern approach to cancer treatment, aiming to develop therapies that target specific mutations driving cancer growth. The company's location in Delaware places it within a region with a strong life sciences ecosystem, including access to research institutions and potential partners. As a clinical-stage company, it has not yet commercialized any products, and its primary activities involve research, preclinical studies, and clinical trials.
What are the main drug candidates in Prelude Therapeutics' (PRLD) pipeline?
Prelude Therapeutics' pipeline includes several novel precision cancer medicines. Its lead candidate targets the JAK2V617F driver mutation, which is a common mutation in myeloproliferative neoplasms such as myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET). The company is also developing a KAT6A inhibitor for the treatment of advanced breast cancer and other solid tumors. Additionally, it has a program focused on mutated calreticulin degrader antibody conjugates, which are designed to treat MF and ET. These candidates are in various stages of preclinical and clinical development, and the company has a collaboration with AbCellera Biologics to advance its degrader antibody conjugate technology.